Cetya Therapeutics is developing HDAC inhibitors which are analogs of largazole, a natural product Class I-restricted HDAC inhibitor. Cetya is focused in two key areas: (i) solid tumor indications in oncology and (ii) hemoglobinopathies such as sickle cell disease. We have drugs with excellent selectivity with early evidence of improved safety.